PHASE I TRIALS OF NEW ANTI-CANCER AGENTS

NIH GUIDE, Volume 22, Number 4, January 29, 1993



RFA:  CA-93-07



P.T. 34



Keywords:

  Clinical Trial 

  Cancer/Carcinogenesis 

  Chemotherapeutic Agents 

  Pharmacology 



National Cancer Institute



Letter of Intent Receipt Date:  February 12, 1993

Application Receipt Date:  March 23, 1993



The Division of Cancer Treatment of the National Cancer Institute

would like to clarify Request for Applications (RFA CA-93-07),

published December 18, 1992 as follows:



The Division of Cancer Treatment (DCT), National Cancer Institute

(NCI) invites cooperative agreement (U01) applications from

institutions wishing to perform Phase I trials of promising

anti-cancer agents in patients with cancer refractory to currently

available therapy and to conduct laboratory studies in support of the

clinical trials such that their conduct leads to a greater

understanding of the relationship between drug administration and

biological changes in patients.  In general patients should be

treated only at the applicant institution, although alternative

arrangements will be considered if well justified.  Support for

laboratory studies may be conducted by collaborators at other

institutions.



The Letter of Intent Receipt date is changed to February 12, 1993.



Under AWARD CRITERIA, the anticipated date of award is corrected to

read December 1, 1993.



INQUIRIES



Dr. David Parkinson, Chief Investigational Drug Branch

Cancer Therapy Evaluation Program

National Cancer Institute

Executive Plaza North, Room 734

Bethesda, MD  20892

Telephone:  (301) 496-5223

FAX:  (301) 480-4663



.

Return to 1993 Index

Return to NIH Guide Main Index

	Office of Extramural Research (OER)			National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892			Department of Health and Human Services (HHS)
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.